Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer’s disease: results of a randomized, double-blind, placebo-controlled phase 2a study

Table 4 Cohen’s d effect size for significant efficacy parameters

Domain	Parameter	ITT population	mITT population	PP population	Effect size^a
CSF	QC activity	1.25***	1.28***	1.66***	↓ large
EEG	Relative theta power	0.29**	0.32***	0.37**	↓ small–moderate
NTB CSF	One Back Test	0.23*	0.23^†	0.20	↓ small
	Neurogranin	0.16^†	0.20*	0.12	↓ small
	YKL-40	0.16^†	0.16^†	0.20*	↓ small

CSF cerebrospinal fluid, EEG electroencephalogram, ITT intent to treat, mITT modified ITT, NTB Neuropsychological Test Battery, PP per protocol, QC glutaminyl cyclase
^aArrow indicates direction of treatment effect (↓ decrease)
^†0.05 < p ≤ 0.10
*0.01 < p ≤ 0.05
**0.001 < p ≤ 0.01
***p ≤ 0.001

ISSN: 1758-9193